Long non-coding RNA AFAP1-AS1 is a novel biomarker in various cancers: a systematic review and meta-analysis based on the literature and GEO datasets

Yumin Wang, Yongzhen Mo, Xiang Yang, Ruoyu Zhou, Zeyu Wu, Yuchen He, Xue Yang, Yaxian Zhong, Yajun Du, Hang Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Zhaoyang Zeng, Can Guo and Wei Xiong _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:102346-102360. https://doi.org/10.18632/oncotarget.21830

Metrics: PDF 2146 views  |   HTML 2693 views  |   ?  


Yumin Wang1,2,3,*, Yongzhen Mo1,2,3,*, Xiang Yang1, Ruoyu Zhou1,2, Zeyu Wu1, Yuchen He1, Xue Yang1,2, Yaxian Zhong1,2, Yajun Du1,2, Hang Zhou1, Xiaoling Li1,2,3, Yong Li2,4, Guiyuan Li1,2,3, Zhaoyang Zeng1,2,3, Can Guo1,2,3 and Wei Xiong1,2,3

1Key Laboratory of Carcinogenesis of Ministry of Health, Xiangya Hospital, Central South University, Changsha, Hunan, China

2Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China

3Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

4Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

*These authors contributed equally to this work

Correspondence to:

Wei Xiong, email: [email protected]

Can Guo, email: [email protected]

Keywords: long noncoding RNA, cancer, AFAP1-AS1, meta-analysis, biomarker

Received: August 06, 2017     Accepted: September 23, 2017     Published: October 11, 2017


Background Growing evidence indicates that AFAP1-AS1 plays an important role in various cancers, suggesting that it might be a potential cancer biomarker.

Materials and Methods: A meta-analysis was performed using microarray data obtained via the Affymetrix Human Genome U133 Plus 2.0 platform (found in the GEO database) and data obtained through a systematic search of PubMed and Web of Science. The pooled odds ratio (OR) and hazard ratio (HR) with 95% CI (confidence interval) were used to judge the value of biomarkers.

Results: A total of 30 studies were included in this meta-analysis, comprising a total of 3573 patients. AFAP1-AS1 was significantly linked with overall survival (OS) (HR = 1.58; 95% CI: 1.12–2.23) and recurrence-free survival (RFS) (HR = 2.32, 95% CI: 1.68–3.19). We found that AFAP1-AS1 was a risk factor in the prognoses of lung cancer (pooled HR: 1.54; 95% CI: 1.01–2.34), digestive system cancer (pooled HR: 1.87; 95% CI: 1.45–2.41) and nasopharyngeal carcinoma (HR: 11.82; 95% CI: 5.09–27.46). AFAP1-AS1 was also a risk factor for RFS in breast cancer (pooled HR = 2.90; 95% CI: 1.69–4.98), as well as TNM stage in both esophageal cancer (pooled OR = 1.90; 95% CI: 1.01–3.57) and colorectal cancer (OR = 6.72; 95% CI: 1.92–23.58). AFAP1-AS1 was significantly associated with lymph node metastasis in clear cell carcinoma (OR = 5.04; 95% CI: 2.36–10.78) and distant metastasis in pancreatic cancer (OR = 11.64; 95% CI: 2.13–63.78).

Conclusions: AFAP1-AS1 can serve as a novel molecular marker predicting tumor progression, patient prognosis and lymph node metastasis in different types of cancers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21830